Research Triangle Park, NC, – December 14, 2009 – Quintiles has been named CRO of the Year by the prestigious SCRIP Awards. The panel of judges highlighted Quintiles’ breadth of services and its outstanding relationships with clients.

The UK-based SCRIP Awards acknowledge excellence in the biopharmaceutical industry and are judged by an illustrious panel of life sciences experts. The award collected by Quintiles was one of the most competitive of the 13 categories, with the longest list of companies to be considered.

John Ratliff, Chief Operating Officer at Quintiles, said, “We are especially pleased to be recognized for how we help our customers navigate risk and seize opportunities in this changing industry landscape we call the new health. It certainly is testimony to our talented and engaged workforce of 23,000 people around the world who roll up their sleeves and deliver for our customers every day.”

The Scrip award follows recognition earlier this year of Quintiles’ leadership. Two independent surveys ranked Quintiles number one across a range of service and reputation attributes, from breadth of service through to therapeutic expertise.

Results from the fourth annual “CRO Industry Update,” an independent survey of executives at pharmaceutical and biotech companies conducted by William Blair & Company in conjunction with CenterWatch, cited Quintiles as the most frequently mentioned favorite CRO. For “Preferred CRO Ranking by Quality,” Quintiles was rated number one, with three times as many votes as the second place competitor.

In a separate industry survey, respondents rated Quintiles number one in 17 of 18 major attributes, often by wide margins. The independently conducted “The 2009 CRO Quality Benchmarking Report” by Industry Standard Research (ISR) asked 160 pharmaceutical and biotechnology executives – all with recent experience working with outsourced development providers – to rate their perceptions of 13 CROs and three non-traditional functional service providers.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit